ABL Bio Secures $55 Million from Eli Lilly for Grabody Platform License and Equity Investment
Friday, December 26, 2025
ABL Bio, a leading South Korean clinical-stage biotech company specializing in bispecific antibodies, has finalized a landmark collaboration with global pharmaceutical giant Eli Lilly and Company. Announced on December 26, 2025, the agreement includes a $40 million upfront payment for the license, research, and collaboration on ABL Bio's proprietary Grabody platform, alongside a $15 million equity investment, totaling $55 million in R&D funding. This deal underscores the growing prominence of Asian biopharma innovators in the global oncology and immunotherapy landscape, particularly in bispecific antibody technologies.
The Grabody platform, ABL Bio's core technology, enables the development of multifunctional antibodies that simultaneously target multiple disease pathways, offering enhanced efficacy in treating complex conditions like cancer. Under the terms of the agreement, both companies are actively engaged in joint research and development on several therapeutic candidates spanning various modalities, including bispecific antibodies, bispecific antibody-drug conjugates (ADCs), and dual-payload ADCs. This partnership builds on an earlier November agreement valued at up to $2.602 billion, highlighting Lilly's long-term commitment to ABL Bio's pipeline.
CEO Sang Hoon Lee emphasized the strategic use of the funding to expand Grabody indications into high-unmet-need areas such as obesity and muscle disorders. Additionally, ABL Bio plans to extend clinical development of its bispecific immuno-oncology candidates into combination therapies and accelerate next-generation ADC programs. The company's robust pipeline includes eight clinical-stage assets: ABL301 (SAR446159, partnered with Sanofi post-Phase 1), ABL001 (tovecimig, FDA Fast Track designated), ABL111 (givastomig, showing promising Phase 1b data in triple combination with nivolumab and chemotherapy at ESMO GI 2025), ABL503 (ragistomig), ABL105 (YH32367), ABL104 (YH32364), ABL103, and ABL202 (CS5001/LCB71). These programs are advancing in multiple countries, including the US, China, Australia, and Korea.
This collaboration exemplifies the Bio Pharma category's momentum in Asia, where South Korea is emerging as a hub for innovative antibody therapies. ABL Bio's state-of-the-art R&D capabilities position it to challenge established players in immuno-oncology and beyond. The influx of capital from Lilly not only validates the Grabody platform's potential but also bolsters ABL Bio's capacity to scale manufacturing and clinical trials, addressing key supply chain challenges in biopharma production.
From a strategic perspective, this deal aligns with broader industry trends toward platform-based licensing agreements, enabling faster pipeline diversification and risk-sharing. For Lilly, it enhances its portfolio in next-generation biologics, complementing its existing investments in ADCs and bispecifics. In the context of Asia's rising R&D investments, such partnerships signal a shift where regional innovators like ABL Bio are co-developing blockbuster candidates with Western majors, potentially reshaping global drug development dynamics.
Regulatory milestones further strengthen ABL Bio's outlook: ABL001's Fast Track status accelerates its path to approval, while ABL111's clinical data supports expansion into gastrointestinal cancers. The company's focus on combination therapies addresses resistance mechanisms in solid tumors, a critical need in oncology. Looking ahead, the $55 million infusion will fund preclinical advancements in obesity—a field exploding with GLP-1 interest—and muscle disorders, tapping into untapped markets.
ABL Bio's growth trajectory reflects South Korea's supportive ecosystem, including government-backed biopharma incentives and world-class manufacturing facilities. This positions the company to navigate geopolitical supply chain risks while ensuring high-quality output. Industry executives view this as a blueprint for B2B collaborations, fostering innovation in Research & Development and Clinical Trials categories. As ABL Bio advances its pipeline, stakeholders anticipate milestone payments and royalties that could propel it toward blockbuster status, reinforcing Asia's role in global life sciences.
In summary, this Lilly partnership not only provides immediate financial runway but also strategic validation, enabling ABL Bio to execute on its vision of transformative therapies. With clinical readouts on the horizon, the deal promises significant value creation for partners and patients alike, highlighting the vibrancy of Asian Bio Pharma innovation.
